Andrew J Gentles
Overview
Explore the profile of Andrew J Gentles including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
101
Citations
20805
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
White B, De Reynies A, Newman A, Waterfall J, Lamb A, Petitprez F, et al.
Nat Commun
. 2024 Nov;
15(1):9783.
PMID: 39532851
No abstract available.
2.
Bao R, Hutson A, Madabhushi A, Jonsson V, Rosario S, Barnholtz-Sloan J, et al.
J Immunother Cancer
. 2024 Oct;
12(10).
PMID: 39461879
Immuno-oncology has transformed the treatment of cancer, with several immunotherapies becoming the standard treatment across histologies. Despite these advancements, the majority of patients do not experience durable clinical benefits, highlighting...
3.
White B, De Reynies A, Newman A, Waterfall J, Lamb A, Petitprez F, et al.
Nat Commun
. 2024 Aug;
15(1):7362.
PMID: 39191725
We evaluate deconvolution methods, which infer levels of immune infiltration from bulk expression of tumor samples, through a community-wide DREAM Challenge. We assess six published and 22 community-contributed methods using...
4.
Ediriwickrema A, Nakauchi Y, Fan A, Kohnke T, Hu X, Luca B, et al.
bioRxiv
. 2024 May;
PMID: 38766031
Hematopoietic multipotent progenitors (MPPs) regulate blood cell production to appropriately meet the biological demands of the human body. Human MPPs remain ill-defined whereas mouse MPPs have been well characterized with...
5.
Sayitoglu E, Luca B, Boss A, Thomas B, Freeborn R, Uyeda M, et al.
Leukemia
. 2024 May;
38(6):1246-1255.
PMID: 38724673
T cells are important for the control of acute myeloid leukemia (AML), a common and often deadly malignancy. We observed that some AML patient samples are resistant to killing by...
6.
Nief C, Hammer P, Wang A, Charu V, Tanweer A, Litkouhi B, et al.
Clin Cancer Res
. 2024 Apr;
30(13):2801-2811.
PMID: 38669067
Purpose: Risk prediction with genomic and transcriptomic data has the potential to improve patient outcomes by enabling clinicians to identify patients requiring adjuvant treatment approaches, while sparing low-risk patients from...
7.
Schwede M, Jahn K, Kuipers J, Miles L, Bowman R, Robinson T, et al.
Leukemia
. 2024 Mar;
38(7):1501-1510.
PMID: 38467769
Acute myeloid leukemia (AML) has a poor prognosis and a heterogeneous mutation landscape. Although common mutations are well-studied, little research has characterized how the sequence of mutations relates to clinical...
8.
Schwede M, Jahn K, Kuipers J, Miles L, Bowman R, Robinson T, et al.
Res Sq
. 2023 Nov;
PMID: 37986825
Acute myeloid leukemia (AML) has a poor prognosis and a heterogeneous mutation landscape. Although common mutations are well-studied, little research has characterized how the sequence of mutations relates to clinical...
9.
Brennan K, Espin-Perez A, Chang S, Bedi N, Saumyaa S, Shin J, et al.
Genome Med
. 2023 Nov;
15(1):98.
PMID: 37978395
Background: The prognosis for patients with head and neck cancer (HNC) is poor and has improved little in recent decades, partially due to lack of therapeutic options. To identify effective...
10.
Sayitoglu E, Luca B, Boss A, Thomas B, Freeborn R, Uyeda M, et al.
bioRxiv
. 2023 Oct;
PMID: 37790561
Significance: AML is a common leukemia with sub-optimal outcomes. We show that AML transcriptional programs correlate with susceptibility to T cell killing. Killing resistance-associated AML programs are enriched in patients...